<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genotypic and phenotypic variants of junctional epidermolysis bullosa (lucidolytic)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genotypic and phenotypic variants of junctional epidermolysis bullosa (lucidolytic)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Genotypic and phenotypic variants of junctional epidermolysis bullosa (lucidolytic)</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup> <colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1">Subtype</td> <td class="subtitle1">Inheritance<br/> Mutated gene<br/> Targeted gene product</td> <td class="subtitle1">Clinical features</td> </tr> <tr> <td>JEB, generalized severe (formerly Herlitz)</td> <td> <ul> <li>Autosomal recessive</li> <li><em>LAMA3</em>, <em>LAMB3</em>, <em>LAMC2</em></li> <li>Laminin-alpha-3 chain of laminin-332</li> <li>Laminin-beta-3 chain of laminin-332</li> <li>Laminin-gamma-2 chain of laminin-332</li> </ul> </td> <td> <ul> <li>Varying degrees of mechanical fragility at birth with generalized, recurrent, often persistent blistering, erosions, and crusting covering not only particularly exposed skin areas (like palms and soles) but most or almost all of the body surface</li> <li>Periungual inflammation, onychodystrophy, and nail loss</li> <li>Exuberant granulation tissue, often periorificial</li> <li>Involvement of oral cavity (blisters, erosions); teeth (enamel hypoplasia, excessive caries); gastrointestinal (protein-losing enteropathy, diarrhea), respiratory, and genitourinary tract; conjunctivae</li> <li>Anemia, growth retardation, high lethality (survival past 1 year of age uncommon)</li> </ul> </td> </tr> <tr> <td>JEB, generalized intermediate (formerly non-Herlitz)</td> <td> <ul> <li>Autosomal recessive</li> <li><em>COL17A1</em>, <em>LAMA3</em>, <em>LAMB3</em>, <em>LAMC2</em></li> <li>Type XVII collagen</li> <li>Laminin-alpha-3 chain of laminin-332</li> <li>Laminin-beta-3 chain of laminin-332</li> <li>Laminin-gamma-2 chain of laminin-332</li> </ul> </td> <td> <ul> <li>Generalized blistering from birth, atrophic scarring, milia; "male-pattern" alopecia; nail dystrophy and loss</li> <li>Involvement of oral cavity and teeth (excessive caries, teeth loss, enamel hypoplasia); gastrointestinal, respiratory, and genitourinary tract; conjunctivae</li> <li>Anemia, growth retardation, protein losing enteropathy, diarrhea</li> </ul> </td> </tr> <tr> <td>JEB, localized</td> <td> <ul> <li>Autosomal recessive</li> <li><em>COL17A1</em>, <em>ITGB4</em>, <em>LAMA3</em>, <em>LAMB3</em>, <em>LAMC2</em></li> <li>Type XVII collagen</li> <li>Integrin-beta-4</li> <li>Laminin-alpha-3 chain of laminin-332</li> <li>Laminin-beta-3 chain of laminin-332</li> <li>Laminin-gamma-2 chain of laminin-332</li> </ul> </td> <td> <ul> <li>Localized disease of lesser extent and lesser severity, onset at birth; milia, nail dystrophy, and loss</li> <li>Involvement of oral cavity and teeth (excessive caries, enamel hypoplasia)</li> <li>Extensive atrophic scarring, hair loss, anemia, impairments of growth and development, ocular abnormalities or alterations affecting gastrointestinal, genitourinary, and respiratory tract mostly absent<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td>JEB with pyloric atresia</td> <td> <ul> <li>Autosomal recessive</li> <li><em>ITGA6</em>, <em>ITGB4</em></li> <li>Integrin-alpha-6</li> <li>Integrin-beta-4</li> </ul> </td> <td> <ul> <li>Gestational hydramnion</li> <li>Generalized and profound blistering from birth, occasionally age-associated amelioration; atrophic scarring; nail dystrophy and loss</li> <li>Association with aplasia cutis congenita</li> <li>Enamel hypoplasia</li> <li>Pyloric atresia</li> <li>Congenital genitourinary malformations</li> <li>Sporadically rudimentary ear anlage</li> </ul> </td> </tr> <tr> <td>JEB, inversa</td> <td> <ul> <li>Autosomal recessive</li> <li><em>LAMA3</em>, <em>LAMB3</em>, <em>LAMC2</em></li> <li>Laminin-alpha-3 chain of laminin-332</li> <li>Laminin-beta-3 chain of laminin-332</li> <li>Laminin-gamma-2 chain of laminin-332</li> </ul> </td> <td> <ul> <li>Blistering predominantly located in intertriginous areas/sites, typically displaying an overall extent that exceeds that observed in patients with JEB, localized<sup>[1]</sup></li> <li>Atrophic scarring, milia, hypo-/hyperpigmentation, dystrophic (or absent) nails</li> <li>Moderate oral mucosal lesions; dental enamel hypoplasia, caries and gastrointestinal abnormalities to a lesser extent as compared with other JEB variants</li> </ul> </td> </tr> <tr> <td>JEB, late onset</td> <td> <ul> <li>Autosomal recessive</li> <li><em>COL17A1</em></li> <li>Type XVII collagen</li> </ul> </td> <td> <ul> <li>Mild form of JEB developing in young adulthood or later</li> <li>Dystrophic (or absent) nails, dental enamel hypoplasia and caries to a lesser severity than JEB, generalized intermediate</li> <li>Hyperhidrosis</li> <li>Absence of dermatoglyphs on fingers, palms, toes, and soles</li> </ul> </td> </tr> <tr> <td>JEB-LOC (laryngo-onycho-cutaneous) syndrome<sup>[2-11]</sup></td> <td> <ul> <li>Autosomal recessive</li> <li><em>LAMA3A</em></li> <li>Laminin-alpha-3a chain of laminin-332</li> </ul> </td> <td> <ul> <li>High incidence in Punjab</li> <li>Minimal skin blistering, erosions</li> <li>Extensive aberrant production of granulation tissue with delayed healing, atrophic scarring</li> <li>Involvement of larynx (altered cry) at birth or later, skin (face, nuchal) and conjunctiva (granulomatous papules, symblepharon) in infancy</li> <li>Nail dystrophy and loss</li> <li>Enamel hypoplasia, caries</li> <li>High childhood mortality due to laryngeal, gastrointestinal, and urethral strictures</li> </ul> </td> </tr> <tr> <td>JEB with respiratory and renal involvement (JEB-RR)<sup>[10-12]</sup></td> <td> <ul> <li>Autosomal recessive</li> <li><em>ITGA3</em></li> <li>Integrin-alpha-3</li> </ul> </td> <td> <ul> <li>Congenital nephrotic syndrome (small kidneys, atrophic glomeruli, focal segmental glomerulosclerosis, diffuse interstitial fibrosis, tubular atrophy and loss)</li> <li>Interstitial lung disease (tachypnea, respiratory distress, cyanosis in first days of life; secondary aspiration with respiratory tract infections)</li> <li>Mild skin fragility (small blisters and erosions beginning at age of 2 to 4 months</li> <li>Fine and sparse scalp hair, eyebrows, eyelashes</li> <li>Nail dystrophy, distal onycholysis</li> <li>Delayed re-epithelialization; healing with residual erythema</li> <li>No scarring; no mucosal involvement</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">JEB: junctional epidermolysis bullosa.</div><div class="graphic_reference">References:
<ol>
<li>Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931.</li>
<li>Shabbir G, Hassan M, Kazmi A. Laryngo-onycho-cutaneous syndrome: A study of 22 cases. Biomedica 1986; 2:15.</li>
<li>Ainsworth JR, Spencer AF, Dudgeon J, et al. Laryngeal and ocular granulation tissue formation in two Punjabi children: LOGIC syndrome. Eye (Lond) 1991; 5:717.</li>
<li>Ainsworth JR, Shabbir G, Spencer AF, Cockburn F. Multisystem disorder of Punjabi children exhibiting spontaneous dermal and submucosal granulation tissue formation: LOGIC syndrome. Clin Dysmorphol 1992; 1:3.</li>
<li>Phillips RJ, Atherton DJ, Gibbs ML, et al. Laryngo-onycho-cutaneous syndrome: An inherited epithelial defect. Arch Dis Child 1994; 70:319.</li>
<li>Murrell DF, Hamil K, Pfendner E, et al. Is Laryngo-Onycho-Cutaneous Syndrome a form of junctional epidermolysis bullosa? Oral paper. Australasian College of Dermatologists' Spring Meeting, Cairns, Australia, September 2005.</li>
<li>Figueira EC, Crotty A, Challinor CJ, et al. Granulation tissue in the eyelid margin and conjunctiva in junctional epidermolysis bullosa with features of laryngo-onycho-cutaneous syndrome. Clin Exp Ophthalmol 2007; 25:163.</li>
<li>Hamil K, Uitto J, Figueira EC, et al. Novel N-terminal mutation in LAMA3a isoform causing late-onset Herlitz junctional epidermolysis bullosa with features of laryngo-onycho-cutaneous syndrome. Poster. Society for Investigative Dermatology, Los Angeles, CA, May 2007.</li>
<li>Cohn HI, Murrell DF. Laryngo-onycho-cutaneous syndrome. Dermatol Clin 2010; 28:89.</li>
<li>Nicolaou N, Margadant C, Lilen MR, et al. Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome. J Clin Invest 2012; 122:4375.</li>
<li>Yalcin EG, He Y, Orhan D, et al. Crucial role of posttranslational modifications of integrin α3 in interstitial lung disease and nephrotic syndrome. Hum Mol Genet 2015; 24:3679.</li>
<li>Has C, Spartà G, Kiritsi D, et al. Integrin α3 mutations with kidney, lung, and skin disease. N Engl J Med 2012; 366:1508.</li>
</ol></div><div id="graphicVersion">Graphic 67202 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
